Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Alkermes To Host Conference Call To Discuss First Quarter 2017 Financial Results April 20, 2017 Growing Catalent Takes Out Cook Pharmica in $950 Million Deal September 18, 2017 Officials Eye New Biotech Tenants for Bristol-Myers' Former Connecticut Complex February 15, 2018
